Additionally, the demographic expression data revealed that both TMPRSS2 and CXCL10 were upregulated in PRAD patients aged 41‒60 years and 61‒80 years respectively with Gleason scores 7 to 9. This evidence concerns the gene TMPRSS2 and prostate adenocarcinoma.